Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.21.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue    
Product revenue, net $ 10,719 $ 11,946
Collaboration revenue 800 0
Revenue - related party 68 972
Net revenue 11,587 12,918
Operating expenses    
Cost of goods sold - product revenue 3,908 3,810
Research and development 20,028 14,867
Research and development - licenses acquired 126 250
Selling, general and administrative 17,542 15,519
Total operating expenses 41,604 34,446
Loss from operations (30,017) (21,528)
Other income (expense)    
Interest income 227 627
Interest expense and financing fee (2,189) (3,125)
Change in fair value of investments 5,913 0
Change in fair value of derivative liability 0 (42)
Total other income (expense) 3,951 (2,540)
Net loss (26,066) (24,068)
Less: net loss attributable to non-controlling interests 17,244 11,698
Net loss attributable to common stockholders $ (8,822) $ (12,370)
Net loss per common share - basic and diluted $ (0.32) $ (0.38)
Net loss per common share attributable to non - controlling interests - basic and diluted (0.21) (0.18)
Net loss per common share attributable to common stockholders - basic and diluted $ (0.11) $ (0.19)
Weighted average common shares outstanding - basic and diluted 80,851,671 63,496,256